Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ingrid Teige"'
Autor:
Eric Quemeneur, Jean-Baptiste Marchand, Ingrid Teige, Matilda Rehn, Linda Mårtensson, Monika Semmrich, Laetitia Fend, Johann Foloppe, Nathalie Silvestre, Björn Frendéus
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Checkpoint inhibitor antibodies have improved survival in a variety of cancers, however, a great unmet need remains since only a small fraction of patients responds. Reasons for lack of efficacy are believed to include lack of tumor infilt
Autor:
Angela Leeming, Björn Frendéus, Alexa A Jordan, Mathilda Kovacek, Yang Liu, Joseph McIntosh, Linda Mårtensson, Michael Wang, William E. Lee, Ingrid Teige, Ingrid Karlsson, Changying Changying Jiang
Publikováno v:
Blood. 136:35-35
Mantle cell lymphoma (MCL) is a rare but aggressive B-cell non-Hodgkin's lymphoma that represents 6% of all lymphomas in the United States. Recent therapies including anti-CD20 antibody rituximab, BTK inhibitors, and BCL-2 inhibitors alone or in comb
Autor:
Johann Foloppe, Ingrid Teige, Nathalie Silvestre, Matilda Rehn, Eric Quéméneur, Jean-Baptiste Marchand, Laetitia Fend, Björn Frendéus, Monika Semmrich, Linda Mårtensson
Publikováno v:
Cancer Research. 80:5602-5602
Oncolytic virotherapy is a clinically validated class of immune modulatory drugs with activity in solid cancer. The mode of action of armed oncolytic Vaccinia viruses (oVV) includes cell death induction following selective replication in tumor cells,
Autor:
Yang Liu, Joseph McIntosh, Mathilda Kovacek, Changying Jiang, Michael L. Wang, Angela Leeming, Rongjia Zhang, Björn Frendéus, Linda Mårtensson, Krystle Nomie, William E. Lee, Ingrid Teige, Ingrid Karlsson
Publikováno v:
Blood. 134:2863-2863
Introduction: Mantle cell lymphoma (MCL) is a rare but aggressive non-Hodgkin lymphoma (NHL). CD20 antibodies (e.g. rituximab), BTK inhibitors (e.g. ibrutinib and acalabrutinib), and BCL-2 inhibitors (e.g. venetoclax) alone or in combination have sho
Autor:
Markus Hansson, Titti Martinsson Niskanen, Guido Tricot, Morten Mau-Sørensen, Morten Salomo, Ashraf Badros, Annika Sundberg, Fritz Offner, Peter Gimsing, Yvonne Stenberg, Stina Wichert, Björn Frendéus, Elisabeth Sonesson, Maurizio Zangari, Magnus Korsgren, Ingrid Teige, Hareth Nahi, Martine Poelman, Jan Van Droogenbroeck
Publikováno v:
Clinical Cancer Research. 21:2730-2736
Purpose: This multicenter, first-in-human study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of BI-505, a human anti-ICAM-1 monoclonal antibody, in advanced relapsed/refractory multiple myeloma patients. Experimental Design:
Publikováno v:
International Immunology. 20:1097-1106
Psoriasis is a common chronic inflammatory skin disease, characterized by epidermal hyperplasia, immune cell infiltration, increased dermal angiogenesis and local up-regulation of a variety of inflammatory mediators. Psoriasis is thought to be driven